Advaxis Nominated for Vaccine Industry Excellence Award

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live bacteria that are bio-engineered to secrete a protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

The company has been selected for the shortlist of the 5th Annual Vaccine Industry Excellence (ViE) Awards in the category of Best Therapeutic Vaccine (approved or in development) for its ADXS-HPV construct. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months.

The ViE Award nominees are voted on by those in the global vaccine industry and also judged by a panel of representatives from pharma, biotech, academia, government, non-governmental organizations (NGOs), and public health. Winners will be announced at the annual ViE Awards on April 11, 2012 during the World Vaccine Congress in Washington, D.C., produced by Terrapinn.

Other nominees in the category include:

  • Antigen Express: AE37 – Breast cancer
  • BioSante Pharmaceuticals: GVAX
  • Galena Biopharma: NeuVax – Breast cancer
  • ImmusanT: Nexvax2 – Celiac disease
  • Inovio Pharmaceuticals: VGX-3100 – Cervical cancer

Details about the ViE Awards are available at the World Vaccine Congress website.

Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases. Over fifteen  distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, and others.

The comments are closed.